Lexaria Bioscience Corp. (NASDAQ: LEXX) disclosed the final results of its Human Pilot Study #5 (GLP‑1‑H25‑5) on February 5 2026, comparing the company’s oral DehydraTECH‑liraglutide (DHT‑LIR) capsules with the injected Saxenda® branded liraglutide (SAX‑LIR).
The one‑week, randomized, double‑blind study enrolled 60 participants and found that DHT‑LIR achieved pharmacokinetic exposure that was comparable to, and in some measures slightly higher than, the injected formulation, while the oral product delivered a markedly lower incidence of gastrointestinal adverse events.
Because the ELISA assay used to quantify liraglutide was affected by background signal noise from plasma protein binding, the pharmacokinetic comparison is qualified; both treatments showed similar temporal patterns, but absolute exposure values should be interpreted with caution.
Gastrointestinal events were reduced by 22.7 % overall, with nausea falling 67 % and overall GI events dropping 31 % relative to Saxenda, underscoring the tolerability advantage of the oral formulation.
Blood glucose, insulin, and body weight changes did not differ significantly between groups, and weight loss was slightly greater in the Saxenda arm; the short duration of the study limits conclusions about long‑term efficacy.
The results support Lexaria’s DehydraTECH platform, which is designed to improve oral delivery of GLP‑1 agents, and align with the company’s 505(b)(2) regulatory strategy that leverages existing data for accelerated approval.
In its most recent quarterly report, Lexaria posted an earnings per share of –$0.07, beating analyst expectations of –$0.13, while revenue reached $0.19 million, a modest figure that reflects the company’s early‑stage focus on intellectual‑property licensing and clinical development.
CEO Richard Christopher said, “We are extremely pleased with the results of Human Pilot Study #5. In addition to achieving the study’s primary safety and tolerability endpoint, we also demonstrated that oral DehydraTECH‑liraglutide functioned comparably to traditionally injected liraglutide, consistent with our regulatory development pathway objectives.”
The study marks a key milestone toward an oral GLP‑1 product that could open a new revenue stream and strengthen Lexaria’s position in the rapidly expanding weight‑loss and diabetes market, though the company remains in a loss‑making phase and will need to secure additional funding or partnerships to bring the product to market.
Lexaria’s platform competes with established injectable GLP‑1 therapies from Novo Nordisk and other biopharmaceuticals; a successful oral product would differentiate the company and potentially attract strategic partners or licensing agreements.
While the data confirm improved tolerability, the limited duration and PK measurement challenges mean that further studies are required to establish efficacy and long‑term safety, but the positive safety profile positions Lexaria favorably for future development and regulatory engagement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.